Physician profile
Ashley C Cavalier
NPI 1558366534
$4,543.93
in general payments reported to CMS, 2019-2025
34 companies · $1,172 in 2025
The $1,172 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $244 · 2021: $420 · 2022: $753 · 2023: $614 · 2024: $1,042 · 2025: $1,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,828.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $625.37 | 2019-2025 | Libtayo, Dupixent |
| Abbvie INC. | $507.05 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $406.16 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Pfizer INC. | $308.51 | 2022-2025 | |
| Revance Therapeutics, INC. | $277.75 | 2024-2025 | Daxxify |
| Leo Pharma INC. | $257.07 | 2021-2025 | Adbry |
| Sun Pharmaceutical Industries INC. | $221.52 | 2019-2024 | Ilumya |
| Galderma Laboratories, L.P. | $199.52 | 2019-2025 | Nemluvio |
| Organon LLC | $175.22 | 2025 | Vtama |
| Almirall LLC | $165.33 | 2021-2025 | Klisyri |
| Genzyme Corporation | $164.12 | 2022-2025 | |
| Amgen INC. | $156.97 | 2020-2025 | Otezla, Enbrel, Otezla |
| Novartis Pharmaceuticals Corporation | $123.90 | 2019-2025 | |
| Lilly USA, LLC | $116.37 | 2019-2025 | Taltz, Ebglyss |
| Incyte Corporation | $101.82 | 2022-2024 | Opzelura |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $93.61 | 2022-2025 | Sotyktu |
| Allergan, INC. | $90.78 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $64.35 | 2020 | |
| Dermira, INC. | $62.55 | 2019-2021 | |
| Organogenesis INC. | $50.80 | 2023 | Puraply |
| Dermavant Sciences, INC. | $43.73 | 2023-2024 | Vtama |
| Ucb, INC. | $41.35 | 2024-2025 | Bimzelx |
| Genentech USA, INC. | $35.63 | 2019-2023 | Erivedge |
| Biofrontera INC. | $35.58 | 2021-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Access Pro Medical, LLC | $26.04 | 2023 | Matriderm |
| Arcutis Biotherapeutics, INC. | $25.62 | 2025 | Zoryve |
| Merck Sharp & Dohme LLC | $25.43 | 2025 | Keytruda |
| Nabriva Therapeutics, Plc | $25.12 | 2022 | |
| Aclaris Therapeutics, INC. | $23.95 | 2019 | |
| Dusa Pharmaceuticals, INC. | $21.77 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.25 | 2023 | Spevigo |
| Botanix Sb INC | $18.39 | 2025 | Sofdra |
| Medtronic, INC. | $16.71 | 2023 | Venaseal |
| Strata Skin Sciences, INC. | $14.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Cavalier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.